Food and Drug Administration Revitalization Act

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Food and Drug Administration Revitalization Act
Great Seal of the United States
Long title An Act to amend the Federal Food, Drug,and Cosmetic Act to revitalize the Food and Drug Administration, and for other purposes.
Enacted by the 101st United States Congress
Effective November 28, 1990
Citations
Public law 101-635
Statutes at Large 104 Stat. 4583
Codification
Acts amended Federal Food, Drug, and Cosmetic Act
Titles amended 21 U.S.C.: Food and Drugs
U.S.C. sections amended
Legislative history

The Food and Drug Administration Revitalization Act was introduced by the 101st Congress of the United States. Senator Orrin G. Hatch was the chairperson sponsor of the federal revitalization amendment for the Food and Drug Administration.

The Title 21 amendment was signed into law on November 28, 1990 by the 43rd President of the United States George H. W. Bush.

Provisions of the Act[edit]

The Food and Drug Administration Revitalization Act of 1990 was penned with four legislative titles establishing a medium for the rejuvenation of the public health agency.


Title I: Administrative and Laboratory Facility Consolidation - 21 U.S.C. § 379b

General Services Administration provided authority to grant contracts for consolidated Food and Drug Administration facilities. The contracts shall be granted for the design, construction, and operation of consolidated Food and Drug Administration facilities.


Title II: Recovery and Retention of Fees for FOIA Requests - 21 U.S.C. § 379c

Charge fees shall be applied to recover reasonable costs incurred in processing Freedom of Information requests for records obtained or created under this Act.


Title III: Scientific Review Groups - 21 U.S.C. § 394

Technical and scientific review groups shall be established as needed to perform functions of the Food and Drug Administration.


Title IV: Automation of FDA - 21 U.S.C. § 379d

Agency shall automate appropriate activities of the Food and Drug Administration to ensure timely review of regulatory activities under this Act.

External links[edit]